MONTI, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.858
EU - Europa 6.766
AS - Asia 4.484
SA - Sud America 495
AF - Africa 130
OC - Oceania 93
Continente sconosciuto - Info sul continente non disponibili 63
Totale 23.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.695
RU - Federazione Russa 2.464
SG - Singapore 1.277
IT - Italia 1.199
CN - Cina 1.032
HK - Hong Kong 748
PL - Polonia 701
IE - Irlanda 610
SE - Svezia 541
VN - Vietnam 482
BR - Brasile 381
KR - Corea 365
DE - Germania 260
FI - Finlandia 254
UA - Ucraina 226
FR - Francia 201
GB - Regno Unito 150
IN - India 130
TR - Turchia 108
JP - Giappone 100
CA - Canada 92
AU - Australia 91
CI - Costa d'Avorio 50
AR - Argentina 42
ID - Indonesia 39
BD - Bangladesh 36
JO - Giordania 33
BE - Belgio 31
NL - Olanda 30
IQ - Iraq 28
CO - Colombia 25
MX - Messico 25
CH - Svizzera 20
EC - Ecuador 19
ZA - Sudafrica 17
ES - Italia 15
NG - Nigeria 14
AE - Emirati Arabi Uniti 13
KE - Kenya 11
PH - Filippine 11
CR - Costa Rica 10
CZ - Repubblica Ceca 10
LT - Lituania 10
SA - Arabia Saudita 10
UZ - Uzbekistan 10
MA - Marocco 9
VE - Venezuela 9
EG - Egitto 8
PK - Pakistan 8
RO - Romania 8
AZ - Azerbaigian 7
HN - Honduras 6
JM - Giamaica 6
MY - Malesia 6
PE - Perù 6
SC - Seychelles 6
TW - Taiwan 6
DO - Repubblica Dominicana 5
PR - Porto Rico 5
TT - Trinidad e Tobago 5
AM - Armenia 4
CL - Cile 4
DK - Danimarca 4
KG - Kirghizistan 4
PY - Paraguay 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BO - Bolivia 3
ET - Etiopia 3
EU - Europa 3
GR - Grecia 3
HU - Ungheria 3
KZ - Kazakistan 3
LB - Libano 3
OM - Oman 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
AT - Austria 2
BG - Bulgaria 2
BY - Bielorussia 2
DZ - Algeria 2
GD - Grenada 2
GT - Guatemala 2
IL - Israele 2
LK - Sri Lanka 2
MD - Moldavia 2
MT - Malta 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
TH - Thailandia 2
VG - Isole Vergini Britanniche 2
AL - Albania 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
Totale 23.817
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.638
Ashburn 1.043
Fairfield 870
Singapore 855
San Jose 746
Warsaw 695
Dublin 609
Hong Kong 609
Chandler 589
Woodbridge 405
Seoul 362
Seattle 356
Cambridge 345
Wilmington 336
Beijing 308
Jacksonville 297
Houston 292
Milan 254
The Dalles 228
Ann Arbor 207
Council Bluffs 204
Buffalo 199
Princeton 157
Ho Chi Minh City 154
Hefei 149
Los Angeles 149
Altamura 136
Lauterbourg 136
Lawrence 131
Rome 110
Boston 103
Hanoi 103
Boardman 102
Tokyo 99
Helsinki 90
Melbourne 87
Mumbai 87
Medford 84
Florence 79
Dallas 77
Izmir 76
Munich 64
New York 57
Abidjan 50
Bremen 48
Shanghai 46
Moscow 45
Phoenix 43
Norwalk 41
San Diego 41
Falls Church 33
Brussels 31
Paris 31
São Paulo 31
Naples 28
Redondo Beach 28
Turku 23
Figino 22
London 22
Da Nang 21
Frankfurt am Main 21
Jakarta 21
Turin 20
Clifton 19
Dearborn 19
Montreal 19
Toronto 19
Bern 18
Bologna 18
Dong Ket 18
Orem 18
Washington 18
Verona 17
Chicago 16
Kent 16
Miano 16
Andover 15
Atlanta 15
Brooklyn 15
Guangzhou 15
Haiphong 14
Hillsboro 14
Abuja 13
Bari 13
Brasília 13
Palermo 13
Stockholm 13
Baghdad 12
San Francisco 12
West Jordan 12
Denver 11
Venice 11
Can Tho 10
Modena 10
Quito 10
Tashkent 10
Charlotte 9
Genoa 9
Hải Dương 9
Manchester 9
Totale 15.841
Salva come PNG Salva come JPEG
Nome #
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 325
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 321
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 304
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 272
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 268
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 264
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 260
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 260
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 260
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 245
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 237
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 236
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 234
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 232
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 229
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 227
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 226
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 221
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 219
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 214
Host genetic determinants in HCV-related mixed cryoglobulinemia 213
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 208
Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma 203
Host genetic determinants in HCV-related mixed cryoglobulinemia 201
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 200
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 195
Analysis of HCV persistence in patients with sustained virological response 195
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 194
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 188
Infection of peripheral mononuclear blood cells by hepatitis C virus 186
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 186
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 186
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 184
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 183
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 183
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 182
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 181
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 180
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 179
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 179
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 179
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 177
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 176
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 175
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 174
Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool? 173
Host genetic determinants in HCV-related mixed cryoglobulinemia 173
HCV INFECTION OF PERIPHERAL AND LIVER MONONUCLEAR-CELLS - PATHOGENIC IMPLICATIONS 172
Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis 172
Tryptophan/kynurenine pathway changes in HCV-infected patients: possible involvement in associated neuropsychiatry pathology 172
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 171
A PROSPECTIVE-STUDY ON THE PREVALENCE OF ANTI HCV ANTIBODIES AND HCV-RNA IN SERA OF HEMODIALYSIS-PATIENTS 170
T(14;18) translocation in chronic hepatitis C virus infection 169
Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications 169
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 169
Can type C hepatitis infection be complicated by malignant lymphoma? 168
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 168
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 165
Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? 164
Vertical transmission of HCV. 164
Applicazione della metodica PCR (polymerase chain reaction) ed altre tecniche di biologia molecolare allo studio dell'infezione da virus C dell'epatite. 161
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 160
Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin's lymphoma 159
Hepatitis C virus infection and B-cell lymphomas 159
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 157
Hepatitis C virus infection in patients with non-Hodgkin's lymphoma 156
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 156
HCV infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. 155
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 155
Behaviour of sustained responders to anti-HCV treatment: may HCV infection be eradicated? 154
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 153
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 153
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 153
Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease 151
Tryptophan/Kynurenine pathway changes in HCV infected patients: possible involvment in associated neuropsychiathy pathology. 150
Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia 149
Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia 149
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 149
ANALYSIS OF HCV INFECTION IN PATIENTS WITH B-CELL NON-HODGKINS-LYMPHOMA 148
Safety and effectiveness of boceprevir triple therapy in patients with mixed cryoglobulinemia 148
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 145
Mixed cryoglobulinemia as a possible preneoplastic disorder 144
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 144
Lack of preferential localization of tumoral mass in B-cell non-Hodgkin's lymphoma associated with hepatitis C virus infection 143
Hepatitis C virus lymphotropism and possible pathogenetic implications 141
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 141
Analysis of HBV/HDV infection in the liver transplant model. 141
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 141
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 140
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 139
Epatite da virus C e terapia interferonica 139
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 139
Comportamento dell'infezione da HCV in pazienti trapiantati per HCC complicante una cirrosi HCV-correlata 138
Interferon-alpha in mixed cryoglobulinemia patients: a randomized crossover controlled trial 136
Tryptophan/kynurenine Patway Changes in HCV-infected Patients: Possible Involvement In Associated Neuropsychiatry Pathology 136
Hepatitis C virus (HCV) infection of fresh and cultured peripheral blood mononuclear cells (PBMNC). 136
L'Impiego dell'INterferone Alfa Ricombinante nel Trattamento della Cirrosi Attiva anti-HCV positiva. 136
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 134
Hepatitis C virus as a lymphotropic agent: Evidence and pathogenetic implications 134
Type C hepatitis and chronic lymphocytic leukaemia 133
Totale 18.135
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.841
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022930 0 0 44 58 46 38 32 70 47 25 204 366
2022/20232.576 247 345 134 187 246 531 356 132 268 16 74 40
2023/2024756 39 118 163 31 46 116 11 150 11 22 24 25
2024/20256.898 223 696 457 1.027 2.342 823 82 376 336 124 225 187
2025/20266.897 817 929 478 439 697 258 848 317 681 441 132 860
2026/2027810 162 212 436 0 0 0 0 0 0 0 0 0
Totale 23.889